IFNG and breast cancer: These data suggest that ADAM17-expressing breast cancer cells, MCF7 and MDA-MB-453, can degrade IFN-γ within a few hours, but the inhibition of enzymatic activity of ADAM17 could completely block ADAM17-dependent IFN-γ degradation.